24 August 2016 - In 2012, Mylan settled a lawsuit by agreeing to allow a generic competitor into the market in 2015, potentially cutting into a big part of its business.

Mylan had already been steadily increasing the price of EpiPen. After the settlement, it started to raise the price even faster.

Now, as Mylan faces growing public furor over its pricing of EpiPen, the company’s history of pricing the product highlights a common tactic in the drug industry: sharply raising prices in the years just before a generic competitor reaches the market, as a sort of final attempt to milk big profits from the brand-name drug.

Read New York Times article